KR930702984A - 비-소세포 폐암의 치료 - Google Patents

비-소세포 폐암의 치료

Info

Publication number
KR930702984A
KR930702984A KR1019930702491A KR930702491A KR930702984A KR 930702984 A KR930702984 A KR 930702984A KR 1019930702491 A KR1019930702491 A KR 1019930702491A KR 930702491 A KR930702491 A KR 930702491A KR 930702984 A KR930702984 A KR 930702984A
Authority
KR
South Korea
Prior art keywords
hydroxy
days
small cell
lung cancer
cell lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019930702491A
Other languages
English (en)
Korean (ko)
Inventor
케이쓰 죤슨 란달
Original Assignee
스튜어트 알. 슈터
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜어트 알. 슈터, 스미스클라인 비참 코포레이션 filed Critical 스튜어트 알. 슈터
Publication of KR930702984A publication Critical patent/KR930702984A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019930702491A 1991-02-21 1992-02-07 비-소세포 폐암의 치료 Ceased KR930702984A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65893791A 1991-02-21 1991-02-21
US658,937 1991-02-21
PCT/US1992/001034 WO1992014471A1 (en) 1991-02-21 1992-02-07 Treatment of non-small cell lung carcinoma

Publications (1)

Publication Number Publication Date
KR930702984A true KR930702984A (ko) 1993-11-29

Family

ID=24643331

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930702491A Ceased KR930702984A (ko) 1991-02-21 1992-02-07 비-소세포 폐암의 치료

Country Status (13)

Country Link
US (1) US5756512A (enExample)
EP (1) EP0572549B1 (enExample)
JP (1) JP2738979B2 (enExample)
KR (1) KR930702984A (enExample)
AT (1) ATE227991T1 (enExample)
AU (2) AU1531992A (enExample)
CA (1) CA2103707C (enExample)
DE (1) DE69232852T2 (enExample)
DK (1) DK0572549T3 (enExample)
ES (1) ES2187500T3 (enExample)
MX (1) MX9200755A (enExample)
PT (1) PT100155B (enExample)
WO (1) WO1992014471A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
AU699436B2 (en) 1998-12-03
EP0572549B1 (en) 2002-11-20
ES2187500T3 (es) 2003-06-16
AU4042795A (en) 1996-02-22
WO1992014471A1 (en) 1992-09-03
PT100155A (pt) 1993-05-31
ATE227991T1 (de) 2002-12-15
DE69232852T2 (de) 2003-09-04
US5756512A (en) 1998-05-26
CA2103707C (en) 2003-12-09
EP0572549A4 (enExample) 1994-01-12
DK0572549T3 (da) 2003-01-06
HK1012267A1 (en) 1999-07-30
EP0572549A1 (en) 1993-12-08
PT100155B (pt) 1999-09-30
MX9200755A (es) 1992-08-01
DE69232852D1 (de) 2003-01-02
CA2103707A1 (en) 1992-08-22
JPH06505741A (ja) 1994-06-30
JP2738979B2 (ja) 1998-04-08
AU1531992A (en) 1992-09-15

Similar Documents

Publication Publication Date Title
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
ES2089027T3 (es) Forma de dosificacion transmucosica.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
RU95105973A (ru) Способ снижения тяжести токсоплазмоза, фармацевтическая композиция, применение производных рифамицина для получения лекарственных препаратов для лечения токсоплазмоза
KR910016931A (ko) 과콜레스테린혈증 치료제
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
KR930702984A (ko) 비-소세포 폐암의 치료
EP0563127B1 (en) Improved treatment method for cancer
KR930702985A (ko) 식도암의 치료
OA07029A (fr) Le chlorure de gallium, nouveau médicament anti-cancéreux.
David et al. Control of chronic pain by dl-alpha acetylmethadol
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
JPS59110620A (ja) 関節炎治療用組成物
KR930702983A (ko) 난소암의 치료
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére
JPH0455172B2 (enExample)
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
Focan et al. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors
KR920011486A (ko) 항종양제
KR940002268A (ko) 21-클로로-프레그난 유도체
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
RU2003121205A (ru) Способ профилактики и (или) лечения анемии у детей (варианты)
Pansy et al. Long-Lasting Antituberculous Activity of Derivatives of 2-Styrylquinoline

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19930820

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19981130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19990512

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19981130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I